Assess whether labeling language overclaims the evidence (7902f6)
August 31, 2026 · SmartSolo
Situation
Disproportionate reporting signal workbook arrived with an inspector asking for batch records you cannot produce this week for pediatric-plan strategist. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on labeling language overclaims the in a 505(b)(2) program relying on literature plus a bridging study.
Decision
Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.
Hypotheses to test
- The population in disproportionate reporting signal workbook is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Clinical and Evidence Strategy file.
- The population in disproportionate reporting signal workbook is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
- A 505(b)(2) program relying on literature plus a bridging study already contained an inspector asking for batch records you cannot produce this week before disproportionate reporting signal workbook arrived; no new Clinical and Evidence Strategy path.
- Provenance on disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.
Analysis required
- Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep.
- Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
- Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.
- For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move labeling language overclaims the for pediatric-plan strategist.
Recommendation
Explore more
More Pharma & Life Sciences prompts
- Assess whether pediatric studies are necessary or waivable (4a10b7)
- Assess whether labeling language overclaims the evidence (a4b09c)
- Assess whether biosimilarity is analytically justified after an FAERS cluster
- Assess whether a CMC change is a comparability or a new product (49870f)
- Assess whether a CMO finding is a delay or a refuse-to-file risk (579c54)
Explore related decision areas
See governed multi-model AI on your own prompt
Compare GPT-5, Claude, and Gemini side by side, with human review and a decision record built in.

